PFE-WI
Pfizer, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 6,
"returned": 6,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "0c8e3754-9f96-4ffe-8ec5-595d60e546f0",
"title": "Earnings call: Alexandria Real Estate Equities posts strong Q1 results By Investing.com",
"description": "Earnings call: Alexandria Real Estate Equities posts strong Q1 results",
"keywords": "",
"snippet": "Alexandria Real Estate Equities (ARE) has reported a robust financial performance for the first quarter of 2024, with significant year-over-year growth in net o...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-alexandria-real-estate-equities-posts-strong-q1-results-93CH-3392868",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEB280W7_L.jpg",
"language": "en",
"published_at": "2024-04-24T09:27:12.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 2.530245,
"sentiment_score": 0.4877,
"highlights": [
{
"highlight": "And then finally before I turn it over to Hallie, I mentioned in our last earnings call our decision to sell 219 East 42nd Street, New York City, the former <em>Pfizer</em> (NYSE: ) headquarters building ultimately for residential use. A very good decision reinforced by the continuing.",
"sentiment": 0.4877,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "083af6dc-407e-4743-9c0c-79c7b3441af8",
"title": "The One Stock That Superinvestors Are Dumping: Is It Time to Sell?",
"description": "As part of the weekly research here at The Acquirer’s Multiple we’re always interested in superinvestors who hold the same stocks that appear in our Acquirer’s Multiple Stock Screeners, based on th…",
"keywords": "",
"snippet": "As part of the weekly research here at The Acquirer’s Multiple we’re always interested in superinvestors who hold the same stocks that appear in our Acquire...",
"url": "https://acquirersmultiple.com/2024/04/the-one-stock-that-superinvestors-are-dumping-is-it-time-to-sell-34/",
"image_url": "https://acquirersmultiple.com/wp-content/uploads/2023/11/USB.jpeg",
"language": "en",
"published_at": "2024-04-24T09:18:23.000000Z",
"source": "acquirersmultiple.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 22.937696,
"sentiment_score": 0,
"highlights": [
{
"highlight": "This week we’ll take a look at:\n\n<em>Pfizer</em> <em>Inc</em> (PFE)\n\n<em>Pfizer</em> is one of the world’s largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.\n\nA quick look at the price chart below for the company shows us that the stock is down 38.36% in the past twelve months.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "180f2c61-9cf8-4536-b325-8009c44c9876",
"title": "Microbial Products Market to Gain $286.53 Billion, by 2033 with 6% CAGR: States The Brainy Insights",
"description": "The global microbial products market size is anticipated to grow from USD 160 billion to USD 286.53 billion in 10 years. The market will experience rapid...",
"keywords": "Brainy Insights Pvt. Ltd., Microbial Products Market",
"snippet": "Newark, April 24, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 160 billion in 2023 global microbial products market will reach USD 286.53...",
"url": "https://www.globenewswire.com/news-release/2024/04/24/2868385/0/en/Microbial-Products-Market-to-Gain-286-53-Billion-by-2033-with-6-CAGR-States-The-Brainy-Insights.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/e0ed2f75-5061-4c4a-a30b-65427e5cc0f4",
"language": "en",
"published_at": "2024-04-24T09:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 9.952314,
"sentiment_score": 0,
"highlights": [
{
"highlight": "• NOVADIGM Therapeutics\n\n• Novartis AG\n\n• <em>Pfizer</em> <em>Inc</em>.\n\n• SANOFI S.A\n\n• VALENT Biosciences Corp.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "5b779261-4dc7-441f-b641-47a52f639e29",
"title": "13 Best Ethical Companies to Invest in 2024",
"description": "In this piece, we will take a look at the 13 best ethical companies to invest in 2024. If you want to skip our overview of ESG stocks, then you can take a look at 5 Best Ethical Companies to Invest in 2024. The relationship of the corporate sector with the well-being of the general […]",
"keywords": "",
"snippet": "In this piece, we will take a look at the 13 best ethical companies to invest in 2024. If you want to skip our overview of ESG stocks, then you can take a look ...",
"url": "https://finance.yahoo.com/news/13-best-ethical-companies-invest-080124437.html?.tsrc=rss",
"image_url": "https://s.yimg.com/ny/api/res/1.2/5S6Sc42B1jVyeCs0hlV6Cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c57583adf086fe869c987a278fed0d9a",
"language": "en",
"published_at": "2024-04-24T08:01:24.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 7.753861,
"sentiment_score": 0.7645,
"highlights": [
{
"highlight": "(NASDAQ:AAPL), <em>Pfizer</em> <em>Inc</em>. (NYSE:PFE), and Walmart Inc. (NYSE:WMT) have transformed people's lives and allowed them to improve their health, stay connected, and shop for countless products affordably. On the other end, some of the most controversial companies in the world are among the most valuable as well.",
"sentiment": 0.7645,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "9286f959-f5ea-4b95-88e8-7ba99a472ca5",
"title": "3 Defensive Stocks to Protect Your Portfolio in 2024",
"description": "Stocks Analysis by The Tokenist (Timothy Fries) covering: British American Tobacco PLC, Pfizer Inc, Anheuser Busch Inbev SA NV, Anheuser Busch Inbev NV ADR. Read The Tokenist (Timothy Fries)'s latest article on Investing.com",
"keywords": "",
"snippet": "After the Iran-Israel situation fizzled out for the time being, the Cboe Volatility Index ( ) dropped from its yearly high of 19.23 to 16.36. Although lowered, ...",
"url": "https://www.investing.com/analysis/3-defensive-stocks-to-protect-your-portfolio-in-2024-200647875",
"image_url": "https://i-invdn-com.investing.com/redesign/images/seo/investingcom_analysis_og.jpg",
"language": "en",
"published_at": "2024-04-23T19:06:00.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 24.494038,
"sentiment_score": -0.6416,
"highlights": [
{
"highlight": "<em>Pfizer</em>\n\nA regular coverage visitor, <em>Pfizer</em> <em>Inc</em> (NYSE: ) is to drugs what AB InBev is to beer. Notwithstanding the controversial vaccine rollout, the global pharmaceutical is likely to avoid severe repercussions given the wide nature of the project.",
"sentiment": -0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nFollowing the $43 billion Seagen acquisition for cancer treatment, <em>Pfizer</em> aligned its 2024 outlook at 8% – 10% operational revenue growth without accounting for revenue from Comirnaty and Paxlovid. The total revenue for the full year 2024 is expected to be in the $58.5 billion to $61.5 billion range.",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> has a fertile pipeline across all major medical fields.\n\nThese range from Abrysvo bivalent vaccine for infants infected with respiratory syncytial virus (RSV) to GBT601 for sickle cell disease, Elrexfio for myeloma, Xtandi for prostate cancer, and Danuglipron for obesity, to name a few.",
"sentiment": -0.8225,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "c5cec8d3-1268-4fb4-9a60-4c3df261b705",
"title": "Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors - Merck & Co (NYSE:MRK)",
"description": "",
"keywords": "",
"snippet": "Loading... Loading...\n\nIn today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct com...",
"url": "https://www.benzinga.com/insights/news/24/04/38382436/understanding-merck-amp-cos-position-in-pharmaceuticals-industry-compared-to-competitors",
"image_url": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
"language": "en",
"published_at": "2024-04-23T15:00:49.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 14.26757,
"sentiment_score": 0.17,
"highlights": [
{
"highlight": "EBITDA (in billions) Gross Profit (in billions) Revenue Growth Merck & Co Inc 906.71 8.56 5.38 -3.11% $-0.77 $10.72 5.78% Eli Lilly and Co 126.09 64.55 19.36 19.91% $3.03 $7.57 28.1% Novo Nordisk A/S 47.09 36.71 16.97 22.01% $28.51 $55.85 36.95% AstraZeneca PLC 36.81 5.55 4.78 2.52% $2.18 $9.72 7.29% Novartis AG 23.20 4.17 4.26 19.99% $4.18 $8.75 7.39% <em>Pfizer</em>",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inc</em> 70.97 1.67 2.53 -3.62% $-1.77 $6.69 -41.34% Sanofi SA 20.56 1.49 2.39 -0.75% $0.42 $8.15 6.5% Bristol-Myers Squibb Co 12.73 3.38 2.27 6.03% $4.45 $8.73 0.62% GSK PLC 13.69 5.02 2.22 2.64% $1.16 $5.63 9.16% Zoetis Inc 28.71 13.31 7.87 10.42% $0.83 $1.49 8.48% Takeda Pharmaceutical Co Ltd 36.74 0.96 1.57 1.53% $314.89 $731.71 1.33% Viatris Inc 225",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "PFE-WI",
"total_documents": 6,
"sentiment_avg": 0.13009999940792719
}
]
}
Other details
Exchange
- New York Stock Exchange
- equity
- N/A
- us